Approval Isn't Access. Here's Why Payers Need Real-World Evidence.

A treatment can clear regulatory review and still run into resistance at the formulary committee. To people outside market access, that feels contradictory. If the drug is approved, hasn't it already proved its value?

Not in the way payers need. Regulators and payers are solving different problems. Regulators ask whether the benefits outweigh the risks based on the submitted evidence. Payers and HTA bodies ask a harder operational question: what will this product do in routine care, for the population we actually cover, at the price being asked?

The budget pressure is real

This shift is not academic. In the United States, CMS projects national health spending to grow 5.6% per year from 2023 through 2032, faster than GDP. Across major markets, the same theme shows up in different language. The OECD's 2025 Health at a Glance report argues that financial pressure is rising and that a renewed focus on value-for-money is essential.

Once that pressure meets advanced therapies with very high upfront prices, value stops being a philosophical concept and becomes a budget constraint. A therapy might be clinically impressive and still create real uncertainty for the people deciding whether it should be broadly covered, restricted, or placed into a managed access arrangement.

Approval answers “can it work?” Coverage asks “will it deliver enough value, for this population, at this price?”

Value is broader than trial efficacy

A positive pivotal trial matters. But it is only one slice of value. Payers want to know whether a treatment remains effective outside ideal study conditions, how durable the benefit looks, what the long-term safety profile may be, whether patients actually stay on therapy, and what happens to hospitalizations, medical costs, and quality of life once the product reaches routine practice.

That is one reason value debates stay messy. There is no single universally accepted framework. ISPOR's special task force has argued that many value frameworks struggle with basic issues like perspective and transparent accounting of costs and benefits. In practice, different stakeholders weight the same evidence differently because they are making different decisions.

This is exactly where trials leave gaps

Randomized trials are still the gold standard for causal inference. But they are not designed to answer every access question. They often use selective populations, relatively short follow-up, tightly managed care pathways, and endpoints optimized for approval rather than reimbursement. In orphan disease and oncology, the evidence package can also include surrogate endpoints, single-arm studies, or small populations where traditional head-to-head evidence is hard to generate.

Those designs can be entirely appropriate. They just do not tell a payer everything it needs to know. What happens in older patients? In sicker patients? In people with multiple comorbidities? Against real-world comparators? Over a longer period than the pivotal trial observed?

RWE is not a backup plan for weak trials. It is the evidence layer that answers the questions trials were never built to answer.

What RWE can actually add

This is where real-world evidence earns its keep. It can show whether clinical benefit holds up in broader populations, clarify long-term or uncommon safety outcomes, quantify adherence and persistence, and measure healthcare resource use that matters directly to payers. It can also help with health economics and outcomes research, including quality of life, patient-reported outcomes, and cost offsets that are difficult to observe in a short registration trial.

Just as importantly, RWE can make the burden of disease legible. If a payer does not have a concrete picture of what a disease costs in hospital stays, progression, disability, or downstream utilization, it is much harder for that unmet need to translate into coverage urgency.

None of this is hypothetical. In 2025, AMCP published payer-focused RWE standards specifically because payers value evidence on real-world outcomes and costs, but do not use it consistently unless the methods, endpoints, and reporting are clear enough for actual coverage decisions.

RWE is already part of access decisions

The important shift is that RWE is no longer sitting off to the side as post-launch storytelling. It is increasingly part of the decision workflow. A 2025 policy review cited evidence that the share of HTA reports including RWE in submissions rose from 6% in 2011 to 39% in 2021.

The pattern is even clearer in disease-specific work. In one review of five European HTA agencies evaluating melanoma drugs, real-world data appeared in 54% of relative effectiveness assessments and 88% of cost-effectiveness analyses. The closer the decision gets to payment and budget impact, the more real-world context tends to matter.

NICE makes the logic explicit through managed access agreements. If a treatment looks promising but remains too uncertain on cost-effectiveness, patients can get access while more evidence is collected, after which the treatment is reassessed for routine NHS use. That is a concrete example of RWE acting as the bridge between early promise and durable reimbursement.

It also changes how payment gets structured

Once reimbursement is tied more directly to real performance, evidence generation and payment design start to blur together. Some arrangements link payment or rebates to outcomes. Others are built to make budget exposure more predictable even when demand is uncertain.

The hepatitis C subscription arrangements approved by Washington and Louisiana are a useful illustration. CMS approved models that used fixed payment structures to expand access while making spending more predictable. The mechanics vary by market, but the strategic point is the same: reimbursement is increasingly being designed around both value and uncertainty, not just list price.

What good payer-grade RWE looks like

Not all RWE is decision-grade. Payer-grade evidence starts with a real decision question. It uses a fit-for-purpose data source, a comparator that reflects actual care, clearly defined endpoints, transparent methods, and enough local relevance to matter to the people writing coverage policy.

It also has to arrive on time. An elegant study that lands after the formulary decision is strategically weaker than a strong, credible study that reaches decision-makers while the access window is still open. That is why infrastructure matters so much. The challenge is no longer just generating evidence. It is generating the right evidence, on the right timeline, for the right decision.

The real role of RWE

Over the next decade, the winners in market access will not just be the teams with strong pivotal trials. They will be the teams that can keep proving value after approval, in the messy world where adherence slips, comorbidities stack up, safety signals emerge slowly, and budgets stay finite.

That is the real role of RWE. Not replacing randomized trials. Closing the gap between approval and access.